Withdrawal of Infliximab or Concomitant Immunosuppressant Therapy in Patients With Crohn's Disease on Combination Therapy (SPARE): A Multicentre, Open-Label, Randomised Controlled Trial

被引：0
|
作者：
Louis, E.
Resche-Rigon, M.
Laharie, D.
机构：
来源：
DISEASES OF THE COLON & RECTUM | 2023年 / 66卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1520 / 1521
页数：2
相关论文
共 50 条
  • [1] Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
    Louis, Edouard
    Resche-Rigon, Matthieu
    Laharie, David
    Satsangi, Jack
    Ding, Nik
    Siegmund, Britta
    D'Haens, Geert
    Picon, Laurence
    Bossuyt, Peter
    Vuitton, Lucine
    Irving, Peter
    Viennot, Stephanie
    Lamb, Christopher A.
    Pollok, Richard
    Baert, Filip
    Nachury, Maria
    Fumery, Mathurin
    Gilletta, Cyrielle
    Almer, Sven
    Ben-Horin, Shomron
    Bouhnik, Yoram
    Colombel, Jean-Frederic
    Hertervig, Erik
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (03): : 215 - 227
  • [2] Withdrawal of infliximab or anti-metabolite therapy in Crohn's Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE)
    Louis, E. J.
    Resche-Rigon, M.
    Laharie, D.
    Satsangi, J.
    Ding, N.
    Preiss, J.
    d'haens, G.
    Picon, L.
    Bossuyt, P.
    Vuitton, L.
    Irving, P.
    Bouhnik, Y.
    Viennot, S.
    Lamb, C.
    Pollock, R.
    Baert, F.
    Nachury, M.
    Mathurin, F.
    Gilletta, C.
    Colombel, J. F.
    Hertervig, E.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I001 - I001
  • [3] WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)
    Louis, Edouard
    Resche-Rigon, Matthieu
    Laharie, David
    Satsangi, Jack J.
    Ding, Nik S.
    Siegmund, Britta
    D'Haens, Geert R.
    Picon, Laurence
    Bossuyt, Peter
    Vuitton, Lucine
    Irving, Peter M.
    Bouhnik, Yoram
    Viennot, Stephanie
    Lamb, Christopher A.
    Pollock, Richard C.
    Baert, Filip J.
    Nachury, Maria
    Fumery, Mathurin
    Gilletta, Cyrielle
    Colombel, Jean Frederic
    Hertervig, Erik
    GASTROENTEROLOGY, 2022, 162 (07) : S216 - S216
  • [4] Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial
    Ponsioen, Cyriel Y.
    de Groof, E. Joline
    Eshuis, Emma J.
    Gardenbroek, Tjibbe J.
    Bossuyt, Patrick M. M.
    Hart, Ailsa
    Warusavitarne, Janindra
    Buskens, Christianne J.
    van Bodegraven, Ad A.
    Brink, Menno A.
    Consten, Esther C. J.
    van Wagensveld, Bart A.
    Rijk, Marno C. M.
    Crolla, Rogier M. P. H.
    Noomen, Casper G.
    Houdijk, Alexander P. J.
    Mallant, Rosalie C.
    Boom, Maarten
    Marsman, Willem A.
    Stockmann, Hein B.
    Mol, Bregje
    de Groof, A. Jeroen
    Stokkers, Pieter C.
    D'Haens, Geert R.
    Bemelman, Willem A.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (11): : 785 - 792
  • [5] Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
    Ehrenpreis, ED
    Kane, SV
    Cohen, LB
    Cohen, RD
    Hanauer, SB
    GASTROENTEROLOGY, 1999, 117 (06) : 1271 - 1277
  • [6] TREATMENT DE-ESCALATION IN CROHN'S DISEASE PATIENTS IN REMISSION UNDER INFLIXIMAB AND IMMUNOSUPPRESSANT THERAPY: THE SPARE TRIAL
    Louis, Edouard
    Resche-Rigon, Matthieu
    Laharie, David
    Ding, Nik
    Irving, Peter
    Lamb, Christopher
    Pollok, Richard
    Colombel, Jean-Frederic
    Hertervig, Erik
    Satsangi, Jack
    GUT, 2022, 71 : A27 - A27
  • [7] Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial
    Kobayashi, Taku
    Motoya, Satoshi
    Nakamura, Shiro
    Yamamoto, Takayuki
    Nagahori, Masakazu
    Tanaka, Shinji
    Hisamatsu, Tadakazu
    Hirai, Fumihito
    Nakase, Hiroshi
    Watanabe, Kenji
    Matsumoto, Takayuki
    Tanaka, Masanori
    Abe, Takayuki
    Suzuki, Yasuo
    Watanabe, Mamoru
    Hibi, Toshifumi
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (06): : 429 - 437
  • [8] A prospective, open-label trial of infliximab in patients with Crohn's disease requiring hospitalization
    Bhatia, JK
    Korelitz, BI
    Panagopoulos, G
    Lobel, E
    Mirsky, F
    Sultan, K
    DiSanti, W
    Chun, A
    Keenan, G
    Mamun, K
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S261 - S261
  • [9] Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial
    Chakravarty, Eliza F.
    Utset, Tammy
    Kamen, Diane L.
    Contreras, Gabriel
    McCune, W. Joseph
    Aranow, Cynthia
    Kalunian, Kenneth
    Massarotti, Elena
    Clowse, Megan E. B.
    Rovin, Brad H.
    Lim, S. Sam
    Majithia, Vikas
    Dall'Era, Maria
    Looney, R. John
    Erkan, Doruk
    Saxena, Amit
    Olsen, Nancy J.
    Ko, Kichul
    Guthridge, Joel M.
    Goldmuntz, Ellen
    Springer, Jessica
    D'Aveta, Carla
    Keyes-Elstein, Lynette
    Barry, Bill
    Pinckney, Ashley
    Mcnamara, James
    James, Judith A.
    LANCET RHEUMATOLOGY, 2024, 6 (03): : e168 - e177
  • [10] Artemisinin combination therapy at delivery to prevent postpartum malaria: A randomised open-label controlled trial
    Tesine, Paula
    Woon, Sze-Ann
    Laman, Moses
    Yadi, Gumul
    Yambo, Phantica
    Kasian, Bernadine
    Lorry, Lina
    Robinson, Leanne J.
    Salman, Sam
    Batty, Kevin T.
    Pomat, William
    Manning, Laurens
    Davis, Wendy A.
    Davis, Timothy M. E.
    Moore, Brioni R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 149
12345